

INFECTION CONTROL



EDITORIAL COMMENT

Recommended Precautions for Patients Undergoing Hemodialysis Who Have AIDS or Non-A, Non-B Hepatitis

Martin S. Favero, PhD

ORIGINAL ARTICLES

Implementing a Successful Hepatitis B Vaccination Program

Linda J. Hanacik, RN, BSN, CIC; Timothy R. Franson, MD;
Jill D. Gollup, RN, BSN; Michael W. Rytel, MD

***Klebsiella oxytoca* Isolates in a General Hospital**

Salvador Alvarez, MD; Joy A. Stinnett, RN; Charles G. Shell, MS;
Steven L. Berk, MD

Evaluation of a Skin Test for Chicken Pox

Alfred L. Florman, MD; Edith T. Umland, MD; Denise Ballou, MS;
Alice H. Cushing, MD; Leroy C. McLaren, PhD; T. John Gribble, MD;
Marilyn H. Duncan, MD

Readers' Forum: Controlling Urges and Infections— Computer System Design for Epidemiology

Richard L. Barr; Robert B. Gerzoff

Cost Containment in Infection Control: Effect of DRGs on Utilization of the Microbiology Laboratory

Raymond C. Bartlett, MD

Clinical Pharmacology of Antibiotics: Do Antibiotics Interfere with Host/Bacterial Interaction?

Atef M. Shibl, PhD

Infection Control and Employee Health: Rubella Prevention Programs

William M. Valenti, MD

Reach for advanced protection.

And help wash away the threat of nosocomial infection with improved formula Dial.

Improved Dial protects you and your patients with an advanced technique that makes the active ingredient 3, 4, 4'-


Trichlorocarbonyl even more effective than before. Dial gives you the effectiveness of bacteriostatic protection in a bar soap as mild as soap can be.



As an important part of any hygiene program, Dial helps in removing patient-acquired microorganisms, reducing nosocomial infections, and providing residual antibacterial action.

In controlled clinical and laboratory tests, Dial has been shown to be effective against ordinary skin flora, as well as pathogenic strains of *Staphylococcus aureus*, *Streptococcus pyogenes*, *Corynebacterium minutissimum*. In both *in vitro* and *in vivo* microbiological tests, Dial demonstrated its superior effectiveness against other bar soaps. Dial proved itself to be

IN VITRO MICROBIOLOGICAL AVAILABILITY TEST



ANTIBACTERIAL EFFECTIVENESS
Length of bar is inversely proportional to the bacterial count.

nearly five times more effective *in vitro* antibacterial efficacy than its leading competitor.

Dial not only has excellent bacteriostatic protection, but is formulated to treat skin gently, even with frequent use. Results of studies using the soap chamber test show that Dial is mild.

Advanced antibacterial effectiveness in a bar soap as mild as soap can be. Reach for Dial. For more information and study references on Advanced Protection Dial, call for our new brochure: Toll-Free 1/800/528-0849.



INSTITUTIONAL

Safe for Scopes



HEPATITIS

Sporicidin, diluted 1:16, inactivates the Hepatitis B Virus in 10 minutes.

(Centers for Disease Control, Phoenix, Arizona)

Courtesy of Olympus and ACMI

Completely disinfects flexible and rigid scopes in 10 minutes with only 0.13% glutaraldehyde.

Safe to use . . . Does not cloud scope lenses nor harm metals, rubber and/or plastics. Does not stain or irritate the hands. No gloves are necessary for safety. Vapors do not irritate the eyes or nostrils.

Most effective . . . The only sterilizing solution which is fully effective against the tubercle bacillus, influenza, hepatitis and enteroviruses when diluted 1 in 16.

Stable . . . Fully effective for 30 days after activation.

Proven . . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.

"Sporicidin, diluted 1 in 16, (0.13% glutaraldehyde), is effective for high level hospital disinfection . . ."

*Centers for Disease Control, Atlanta, GA
(Guidelines . . . revised August 1982)*

"This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin."

*Journal of Dental Research, Vol. 60, March 1981
(U.S. Army Institute of Dental Research, Wash., DC)*

"Sporicidin . . . was both more stable and more active against test spores than . . . Cidex and Cidex-7."

Infection Control, 1(2): 90-93, 1980



The Sporicidin Company

4000 Massachusetts Avenue, NW, Washington, DC 20016 Call Toll Free (800) 424-3733

<https://doi.org/10.1017/S0195942800000000>

INFECTION CONTROL®

Table of Contents

Editorial Comment

- Recommended Precautions for Patients Undergoing Hemodialysis Who Have AIDS or Non-A, Non-B Hepatitis** 301
Martin S. Favero, PhD

Original Articles

- Implementing a Successful Hepatitis B Vaccination Program** 306
Linda J. Hanacik, RN, BSN, CIC; Timothy R. Franson, MD;
Jill D. Gollup, RN, BSN; Michael W. Rytel, MD
- Klebsiella oxytoca* Isolates in a General Hospital** 310
Salvador Alvarez, MD; Joy A. Stinnett, RN;
Charles G. Shell, MS; Steven L. Berk, MD
- Evaluation of a Skin Test for Chicken Pox** 314
Alfred L. Florman, MD; Edith T. Umland, MD;
Denise Ballou, MS; Alice H. Cushing, MD;
Leroy C. McLaren, PhD; T. John Gribble, MD;
Marilyn H. Duncan, MD
- Readers' Forum: Controlling Urges and Infections—
Computer System Design for Epidemiology** 317
Richard L. Barr; Robert B. Gerzoff
- Cost Containment in Infection Control: Effect of
DRGs on Utilization of the Microbiology Laboratory** 323
Raymond C. Bartlett, MD
- Clinical Pharmacology of Antibiotics: Do Antibiotics
Interfere with Host/Bacterial Interaction?** 326
Atef M. Shibl, PhD
- Infection Control and Employee Health:
Rubella Prevention Programs** 329
William M. Valenti, MD

Departments

- | | | | |
|--------------------------------|-----|-------------------------------|-----|
| Information for Authors | 293 | Calendar of Events | 333 |
| Letters to the Editor | 298 | Classified Marketplace | 336 |

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.

Copyright 1985: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions. Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, Mansui Bldg., 9-18, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101, Japan. Subscription rates in the US and possessions: Individual: One year—\$50.00; Two years—\$74.00; Three years—\$94.00. Institutional: One year—\$62.00; Two years—\$86.00; Three years—\$106.00; all other countries: \$15.00 additional each year. Single copies of current issues may be obtained for \$5.00, United States and possessions; \$8.00 all other countries.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. **Postmaster:** Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

EDITOR

Richard P. Wenzel, MD
Charlottesville, Virginia

SENIOR ASSOCIATE EDITOR

William Schaffner, MD
Nashville, Tennessee

ASSOCIATE EDITORS

Sue Crow, RN, MSN
Shreveport, Louisiana

John E. McGowan, Jr., MD
Atlanta, Georgia

Dennis G. Maki, MD
Madison, Wisconsin



SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086

Publisher
Richard N. Roash

Associate Publisher
Eric Baloff

Executive Editor
Donna Carpenter

Assistant Editor
M. Lynne Stanwood

Circulation Manager
Kevin J. Fenton

Advertising Manager
Randall Roash

**Classified
Advertising Representative**
Lorraine Giles

EDITORIAL

ADVISORY BOARD

Robert C. Aber, MD
Hershey, Pennsylvania

Charles S. Bryan, MD
Columbia, South Carolina

John P. Burke, MD
Salt Lake City, Utah

Marie B. Coyle, PhD
Seattle, Washington

Burke A. Cunha, MD
Mineola, New York

Richard E. Dixon, MD
Trenton, New Jersey

Harvey A. Elder, MD
Loma Linda, California

Bruce Farber, MD
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD
Portland, Oregon

Richard A. Garibaldi, MD
Farmington, Connecticut

Donald A. Goldmann, MD
Boston, Massachusetts

Dieter H.M. Gröschel, MD
Charlottesville, Virginia

Peter A. Gross, MD
Hackensack, New Jersey

Karen Hadley, RN, MPH
New Orleans, Louisiana

David K. Henderson, MD
Bethesda, Maryland

Peter N.R. Heselbine, MD
Los Angeles, California

Cyrus C. Hopkins, MD
Boston, Massachusetts

Allen B. Kaiser, MD
Nashville, Tennessee

Harold Laufman, MD, PhD
New York, New York

William J. Ledger, MD
New York, New York

Barbara McArthur, RN, PhD
Detroit, Michigan

Rob Roy MacGregor, MD
Philadelphia, Pennsylvania

C. Glen Mayhall, MD
Richmond, Virginia

Ronald Lee Nichols, MD
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD
Richmond, Virginia

James E. Peacock, Jr., MD
Winston-Salem, North Carolina

Frank S. Rhame, MD
Minneapolis, Minnesota

William A. Rutala, PhD, MPH
Chapel Hill, North Carolina

William E. Scheckler, MD
Madison, Wisconsin

Robert J. Shannon, MSPH
Boston, Massachusetts

Walter E. Stamm, MD
Seattle, Washington

Charles W. Stratton, MD
Nashville, Tennessee

Timothy R. Townsend, MD
Baltimore, Maryland

William M. Valenti, MD
Rochester, New York

James Veazey, MD
Albany, New York

Kathy J. Wydra, RN
Geneva, New York

FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.
Birmingham, England

Professor G. Berencsi
Szeged, Hungary

Professor Jaap Dankert
Groningen, Netherlands

Professor Dr. F. Daschner
Freiburg, West Germany

Lars O. Kallings, MD
Stockholm, Sweden

Professor W.B. Kędzia
Sieroca, Poland

Professor A.P. Krasilnikow
Minsk, USSR

Professor Dr. W. Marget
Munich, West Germany

Bertil Nyström, MD
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.
London, England

Samuel Ponce de Leon, MD
Mexico City, Mexico

Hans Reber, MD
Basel, Switzerland

Professor Gerald Reybrouck
Leuven, Belgium

Manfred L. Rotter, MD, DipBact
Vienna, Austria

Theodore Sacks, MD
Jerusalem, Israel

Dr. Bernhard M. Thimm
Federal Republic of Germany

Professor Dr. med. H.P. Werner
Mainz, West Germany

Professor Dr. W. Weuffen
Greifswald, German Democratic Republic


Second International Symposium on Infection Control

London, England
August 11-14, 1986

In 1983 the University of Virginia Medical School, the Austrian Society for Hygiene, Microbiology, and Preventive Medicine and the Editor and Publisher of *Infection Control* sponsored the First International Symposium on Infection Control. The venue was Vienna, and almost 500 specialists from 38 countries attended the sessions to exchange ideas.

The same scientific committee has organized a second symposium in the historic city of London in the summer of 1986. Special features of the London Symposium include sessions on infection control issues of hospitalized children and parturients and of patients in third world countries. We plan to discuss new antibiotics to prevent and treat hospital-acquired infections and new devices which may pose risks for patients. Furthermore, there will be open poster sessions and brief oral presentations in addition to the discussions by invited lecturers. All question-answer periods will be sufficiently long to invite provocative arguments from experts throughout the world. The meetings will be held in spacious accommodations near Hyde Park within walking distance of several excellent hotels.

The scientific committee looks forward to another exciting meeting and invites your participation to insure a successful symposium.



Richard P. Wenzel, MD
Professor of Medicine
Hospital Epidemiologist
University of Virginia Medical Center
Charlottesville, Virginia
Editor, *Infection Control*

Scientific Committee

Richard P. Wenzel, MD
Dieter H.M. Gröschel, MD
Manfred Rotter, MD
William Schaffner, MD
Graham Ayliffe, MD